Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mascha Binder

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Leukemia|June 21, 2020
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyMaxi Wass, Stefanie Göllner, Birgit Besenbeck, et al.
Blood|January 25, 2023
Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptomsAmelie Jaeger, Sudheer Madan Mohan Gambheer, Xiaoyang Sun, et al.
The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.
Blood|August 29, 2013
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stromaIsabel Ben-Batalla, Alexander Schultze, Mark Wroblewski, et al.
Nature Communications|February 2, 2024
Mutation-specific CAR T cells as precision therapy for IGLV3-21<sup>R110</sup> expressing high-risk chronic lymphocytic leukemiaFlorian Märkl, Christoph Schultheiß, Murtaza Ali, et al.
Oncoimmunology|July 8, 2022
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtypeSandra van Wilpe, Donjetë Simnica, Peter Slootbeek, et al.
Med (New York, N.Y.)|April 12, 2025
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trialAnna Brandt, Konrad Klinghammer, Christoph Schultheiss, et al.
British Journal of Haematology|January 5, 2026
High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia to the British Journal of HaematologyPaul Schmidt-Barbo, Christoph Schultheiss, Annaïse J Jauch, et al.
British Journal of Haematology|January 7, 2026
Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia for the British Journal of HaematologyAnnaïse J Jauch, Paul Schmidt-Barbo, Christoph Schultheiss, et al.
British Journal of Haematology|March 18, 2020
Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan AfricaNikolaus C S Mezger, Jana Feuchtner, Mirko Griesel, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Leukemia|June 21, 2020
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyMaxi Wass, Stefanie Göllner, Birgit Besenbeck, et al.
Blood|January 25, 2023
Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptomsAmelie Jaeger, Sudheer Madan Mohan Gambheer, Xiaoyang Sun, et al.
The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.
Blood|August 29, 2013
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stromaIsabel Ben-Batalla, Alexander Schultze, Mark Wroblewski, et al.
Nature Communications|February 2, 2024
Mutation-specific CAR T cells as precision therapy for IGLV3-21<sup>R110</sup> expressing high-risk chronic lymphocytic leukemiaFlorian Märkl, Christoph Schultheiß, Murtaza Ali, et al.
Oncoimmunology|July 8, 2022
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtypeSandra van Wilpe, Donjetë Simnica, Peter Slootbeek, et al.
Med (New York, N.Y.)|April 12, 2025
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trialAnna Brandt, Konrad Klinghammer, Christoph Schultheiss, et al.
British Journal of Haematology|January 5, 2026
High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia to the British Journal of HaematologyPaul Schmidt-Barbo, Christoph Schultheiss, Annaïse J Jauch, et al.
British Journal of Haematology|January 7, 2026
Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia for the British Journal of HaematologyAnnaïse J Jauch, Paul Schmidt-Barbo, Christoph Schultheiss, et al.
British Journal of Haematology|March 18, 2020
Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan AfricaNikolaus C S Mezger, Jana Feuchtner, Mirko Griesel, et al.
Pageof 15